Vistagen Therapeutics Inc (NASDAQ:VTGN) Short Interest Update

Vistagen Therapeutics Inc (NASDAQ:VTGN) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 2,880,000 shares, a growth of 15.2% from the December 15th total of 2,500,000 shares. Approximately 7.6% of the shares of the company are sold short. Based on an average daily volume of 849,800 shares, the short-interest ratio is currently 3.4 days.

Several equities research analysts have recently commented on VTGN shares. ValuEngine lowered Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 27th. Chardan Capital restated a “neutral” rating on shares of Vistagen Therapeutics in a research note on Monday, December 2nd. Maxim Group set a $4.00 price objective on Vistagen Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 15th. Finally, William Blair lowered Vistagen Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 14th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $2.35.

NASDAQ:VTGN opened at $0.66 on Wednesday. The company has a debt-to-equity ratio of 2.44, a current ratio of 1.14 and a quick ratio of 1.14. The firm has a market capitalization of $28.09 million, a price-to-earnings ratio of -0.73 and a beta of -0.41. Vistagen Therapeutics has a one year low of $0.29 and a one year high of $1.86. The business has a fifty day moving average price of $0.64 and a 200-day moving average price of $0.77.

Vistagen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, equities research analysts expect that Vistagen Therapeutics will post -0.4 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Vistagen Therapeutics in the 3rd quarter worth $65,000. Wells Fargo & Company MN purchased a new stake in Vistagen Therapeutics in the 2nd quarter worth $31,000. Vanguard Group Inc. increased its stake in Vistagen Therapeutics by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock worth $868,000 after buying an additional 35,729 shares in the last quarter. LPL Financial LLC purchased a new stake in Vistagen Therapeutics in the 2nd quarter worth $27,000. Finally, D.A. Davidson & CO. increased its stake in Vistagen Therapeutics by 27.3% in the 3rd quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock worth $112,000 after buying an additional 22,500 shares in the last quarter. Hedge funds and other institutional investors own 8.75% of the company’s stock.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Read More: What are no-load funds?

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.